ArticleJournal of virology2018
Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.
Article in Journal of virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Long-term effect of temporary ART initiated during primary HIV-1 infection on viral persistence.Nature communications · 2025Trial
- Time to viral rebound and safety after antiretroviral treatment interruption in postpartum women compared with men.AIDS (London, England) · 2019Trial
- The role of analytical treatment interruptions in shaping HIV-specific immunity and HIV cure.Current opinion in HIV and AIDS · 2025Review
- Intact HIV DNA decays in children with and without complete viral load suppression.PLoS pathogens · 2025Article
- Preferential selection of viral escape mutants by CD8+ T cell 'sieving' of SIV reactivation from latency.PLoS pathogens · 2023Article
- Antiretroviral treatment interruption and resumption within 16 weeks among HIV-positive adults in Jinan, China: a retrospective cohort study.Frontiers in public health · 2023Article
- Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design.The Journal of infectious diseases · 2022Article
- Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Observational
- Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.Current HIV/AIDS reports · 2021Review
- Transient viral replication during analytical treatment interruptions in SIV infected macaques can alter the rebound-competent viral reservoir.PLoS pathogens · 2021Article
- Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound.Scientific reports · 2020Article
- Immune Checkpoints in Viral Infections.Viruses · 2020Review
- Review
- CD8Nature reviews. Immunology · 2020Review
- Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription.Journal of the International AIDS Society · 2020Article
- Article
- Impact of Treatment Interruption on HIV Reservoirs and Lymphocyte Subsets in Individuals Who Initiated Antiretroviral Therapy During the Early Phase of Infection.The Journal of infectious diseases · 2019Article
- Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.The lancet. HIV · 2019Article
- CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV.Frontiers in immunology · 2019Review
- Insight into treatment of HIV infection from viral dynamics models.Immunological reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 1 country.
Funding
Abstract
Analytic treatment interruption (ATI) studies are required to evaluate strategies aimed at achieving ART-free HIV remission, but the impact of ATI on the viral reservoir remains unclear. We validated a DNA size selection-based assay for measuring levels of integrated HIV DNA and applied it to assess the effects of short-term ATI on the HIV reservoir. Samples from participants from four AIDS Clinical Trials Group ATI studies were assayed for integrated HIV DNA levels. Cryopreserved peripheral blood mononuclear cells (PBMCs) were obtained for 12 participants with available samples pre-ATI and approximately 6 months after ART resumption. Four participants also had samples available during the ATI. The median duration of ATI was 12 weeks. Validation of the HIV integrated DNA size-exclusion (HIDE) assay was performed using samples spiked with unintegrated HIV DNA, HIV-infected cell lines, and participant PBMCs. The HIDE assay eliminated 99% of unintegrated HIV DNA species and strongly correlated with the established Alu-
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.